Herein, we evaluate ADT-007, a novel pan-RAS inhibitor, and benchmark its potency and selectivity against other known apoptosis inducers, bortezomib and YM155, for killing KRAS-mutant cancer cells using 3D BEST derived from KRAS-mutant (HCT-116) and WT RAS (HT29) CRC cells. This evidence concerns the gene KRAS and cancer.